Imran Sajid
Imran Sajid has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Guanyu Wang
Laboratory of Biocomplexity and Engineering Biology, Department of Biomedical Engineering, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; CUHKSZ-STEM Joint Laboratory of Precision Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; Ciechanover Institute of Precision and Regenerative Medicine, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China
1 shared publication - Javed Akhtar
Provincial Hospital Affiliated to Shandong University
1 shared publication - Jiahe Wang
School of Biological Sciences and Parker H. Petit Institute for Bioengineering and Bioscience,Georgia Institute of Technology,Atlanta,United States, USA
1 shared publication - Muhammad Imran
Department of Computer Science,Institute of Southern Punjab,Multan,Pakistan, Pakistan
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by MDPI AG in Preprints.org
Single-Cell FRET Imaging: A Robust Biophysical Platform to Resolve Heterogeneity in Metabolic Dysfunction and Cancer Drug Resistance
Cells with similar endpoint measurements can have different biochemical response histories. Time-lapse single-cell Förster resonance energy transfer (FRET) imaging can distinguish these histories and test their relationship to metabolic function and cancer-cell fate. We connect FRET biophysics, biosensor design, and quantitative measurement to interpret cellular heterogeneity in metabolic dysfunction and cancer drug resistance. We emphasize corrected sensitized emission FRET imaging, distinguish corrected ratios from physical transfer efficiency, and describe controls for reporter specificity, temporal fidelity, and reproducibility. In metabolism, FRET imaging can reveal graded or bistable behavior and characterize sensitivity, response amplitude, history dependence, and coupling between signaling and substrate handling. In cancer, time-lapse signaling measurements paired with independent cell-fate outcomes can distinguish incomplete inhibition, adaptive recovery, and survival despite sustained pathway suppression. Cell culture, organoid, and intravital studies illustrate these capabilities and limits. Linking calibrated response histories to independent functional outcomes provides a robust foundation for candidate dynamic biomarkers. Integrating trajectory features with molecular profiles using machine learning could identify candidate predictors of treatment response. Future studies should test whether these dynamic features improve compound selection, combination design, and treatment schedules beyond baseline activity, initial inhibition, and endpoint measurements, with validation in independent patient-derived and in vivo models.
- 5 November 2026
- Published by MDPI AG in Preprints.org
Open AccessSingle-Cell FRET Imaging: A Robust Biophysical Platform to Resolve Heterogeneity in Metabolic Dysfunction and Cancer Drug Resistance
Cells with similar endpoint measurements can have different biochemical response histories. Time-lapse single-cell Förster resonance energy transfer (FRET) imaging can distinguish these histories and test their relationship to metabolic function and cancer-cell fate. We connect FRET biophysics, biosensor design, and quantitative measurement to interpret cellular heterogeneity in metabolic dysfunction and cancer drug resistance. We emphasize corrected sensitized emission FRET imaging, distinguish corrected ratios from physical transfer efficiency, and describe controls for reporter specificity, temporal fidelity, and reproducibility. In metabolism, FRET imaging can reveal graded or bistable behavior and characterize sensitivity, response amplitude, history dependence, and coupling between signaling and substrate handling. In cancer, time-lapse signaling measurements paired with independent cell-fate outcomes can distinguish incomplete inhibition, adaptive recovery, and survival despite sustained pathway suppression. Cell culture, organoid, and intravital studies illustrate these capabilities and limits. Linking calibrated response histories to independent functional outcomes provides a robust foundation for candidate dynamic biomarkers. Integrating trajectory features with molecular profiles using machine learning could identify candidate predictors of treatment response. Future studies should test whether these dynamic features improve compound selection, combination design, and treatment schedules beyond baseline activity, initial inhibition, and endpoint measurements, with validation in independent patient-derived and in vivo models.